Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study

This publication has 16 references indexed in Scilit:

• Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors
  Blood, 1998
• Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 1998
• International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina
  Circulation, 1998
• A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina
  New England Journal of Medicine, 1998
• Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
  New England Journal of Medicine, 1998
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
  The Lancet, 1997
• The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy
  European Heart Journal, 1995
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
  BMJ, 1994
• The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
  New England Journal of Medicine, 1992
• Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.
  Circulation, 1990